00:00Stocks tied to psychedelic therapeutics jumping today in a big way after President Donald
00:04Trump's executive order aimed at faster research and access to once taboo treatments.
00:10The new order directs the FDA to lean on a so-called breakthrough designation to cut
00:15down their review times to one to two months.
00:19Previously, that was six to ten months.
00:21I'm pleased to say that we're joined live now by FDA Commissioner Marty McCary.
00:25Great to have you with us.
00:27And I do want to talk about, you know, why this research, why prioritize it now?
00:32Because, I mean, some of the issues that we're talking about, these are things that have been
00:36discussed for years.
00:38So bring us to this moment.
00:40Well, this is a historic moment in American medicine.
00:44Fifty million dollars is going to be allocated to this type of research.
00:46We've seen some preliminary data that is promising.
00:49That is, remission rates of 30 to 40 percent for PTSD conditions where there's otherwise
00:56no good treatment.
00:57We've also heard dramatic stories of veterans having a profound benefit.
01:03And those individual stories are a form of data, too.
01:06That is scientific data.
01:08We just need to see all of it together and assure safety and efficacy.
01:11See, the applications around these products are now getting to the point where they're mature
01:16enough where the applications are about to arrive here at the FDA.
01:21So we are issuing three national priority vouchers to get a decision out in one to two months
01:26instead of the typical year, in addition to the research funding, and a new pathway so
01:31that it will not be considered a controlled substance at the time of administration in a
01:36controlled medical setting.
01:37I think this has been an issue where, for a long time, there's been some good preliminary
01:42data.
01:42We now have to take a hard look at that data.
01:45And for those suffering with PTSD and other debilitating addictions, we owe it to them
01:50to get those decisions out quickly.
01:52And so there's a lot of focus here on ibogaine, which is, I understand it is a psychedelic compound
01:57that's extracted from an African plant.
02:00And when it comes to, you know, the FDA, that new guidance that you were directed to give
02:05to researchers to study ibogaine, do you expect that the U.S. is going to reclassify ibogaine
02:13and other psychedelic-controlled substances to make it easier to study them?
02:18And if so, is there any sort of timeline you can give us?
02:21Well, not only do we allocate funding to study drugs like ibogaine, but also created a pathway
02:28so that normally when there's an FDA approval, there's a temporary rescheduling to enable
02:34clinicians to use it, that we have that with fentanyl and a number of drugs that are used
02:38in the operating room in America every day.
02:41So that is our normal process.
02:43We want it to be expeditious.
02:44We don't want red tape to slow this down.
02:47And that's because the stories that we're hearing are pretty amazing stories.
02:54Now, we need to do the proper phase three clinical trials because if we recommend these treatments
03:00as a physician community to patients, they want to know what the numbers are.
03:05There are side effects.
03:06People have died from these medications.
03:08But on Saturday with President Trump, I did announce the first ever clearance of an investigational
03:15new drug registration for noribogaine, a form of ibogaine, for first in human trials.
03:21That'll pave the way for the proper clinical studies to be done.
03:25I am curious about some of the studies that have already been done on some of these compounds.
03:29Of course, there was a lot of controversy a few years ago when the FDA rejected, I think
03:34it was an application for basically MDMA or what we would call MDMA.
03:38And the idea there was that despite whatever evidence the trials showed about the benefit,
03:44there was some concern about safety.
03:47What's changed since that rejection in 2024 and where we are today?
03:52Well, that company has gone back and done an audit.
03:55If that company submits the results of their audit for the protocol violation that was cited
04:01in the rejection about two years ago before I was leading the FDA, then that'll be considered
04:07in due process.
04:09But there are side effects that require that there are conditions that are strictly followed
04:17to administer these medications.
04:19For example, patients can become highly amorous.
04:22There needs to be close supervision, not just in a one-on-one setting.
04:26And we want to make sure that there's adequate time to monitor patients if they have cardiovascular
04:34complications, which have been well described with substances like ibogaine.
04:38Now, ibogaine is the least mature of all the studies that are done in the United States.
04:43We have applications that are coming for other psychedelics, and they should be arriving this
04:48summer.
04:48Some of those will get the priority voucher approval.
04:51But given the degree of urgency around this problem, remember, 89% of vets with PTSD are just
04:58getting antidepressants with SSRIs.
05:00It is very low effectiveness.
05:02It's not working well.
05:03We can do better.
05:04So we owe it to them to get decisions out quickly.
05:07All right, Marty, I do, before we let you go, I do have to just ask you about some of
05:10the
05:10other things going on at the FDA, particularly with regards to the recent departure here
05:15of the head of the vaccine program.
05:17Are you any closer to finding a replacement for him?
05:21Yeah, well, the vaccine program lives within our Center for Biologics.
05:25The head of the Center for Biologics was on a sabbatical leave of absence from a university.
05:30He said at the end of the month, he will be going back to the university.
05:34We have a lot of people who are interested in that job, a very robust search.
05:39And I expect an announcement soon.
05:41There are some outstanding candidates.
05:43A lot of people want to work at the FDA.
05:45We're hiring about 3,000 scientists and inspectors at the FDA.
05:50So we are growing.
05:52And it's a great time to be working at the FDA.
05:54So we won't be working at the FDA.
05:54So we'll be starting with a criminal banking.
Comments